The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40–50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors / A.M. Carella, P. Corradini, A. Mussetti, U. Ricardi, U. Vitolo, S. Viviani. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 97:8(2018), pp. 1301-1315. [10.1007/s00277-018-3366-x]

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

P. Corradini;A. Mussetti;
2018

Abstract

The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40–50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.
Allografting; New salvage treatments; Relapsed/refractory Hodgkin lymphoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Hodgkin Disease; Humans; Immunoconjugates; Immunomodulation; Neoplasm Staging; Positron-Emission Tomography; Retreatment; Salvage Therapy; Treatment Outcome; Vinblastine; Molecular Targeted Therapy; Hematology
Settore MED/15 - Malattie del Sangue
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Carella2018_Article_TreatmentOfClassicalHodgkinLym.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 525.96 kB
Formato Adobe PDF
525.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/584814
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact